21 days ago | By News Center
Katherine Yelick has been honored by HPCwire as their Editor's Choice for Outstanding Leadership in high-performance computing. (Photo courtesy of Berkeley Lab Computing Sciences)
Katherine Yelick, the associate laboratory director for Computing Sciences at the U.S. Department of Energy's Lawrence Berkeley National Laboratory and professor of electrical engineering and computer sciences at UC Berkeley, has been honored by HPCwire as their Editor's Choice for Outstanding Leadership in HPC.
The award was presented today at the 2019 International Conference for High Performance Computing...
Read more ...
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...
Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at... Read more ...
Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug... Read more ...
A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat... Read more ...
Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the... Read more ...
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other... Read more ...
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions... Read more ...
The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers... Read more ...
Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3... Read more ...
After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...
LA JOLLA-In mouse models of Alzheimer's disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, Salk... Read more ...